05 Nov, 2021 Results from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at ASN Kidney Week 2021
Positive results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1), were presented as part of the late-breaking session at the American Society of Nephrology (ASN) Kidney Week 2021 virtual meeting held on November 4-7.
Lieske, et al. – “Modeling the risk of progression to kidney failure in patients with primary hyperoxaluria type 1 treated with lumasiran relative to a natural history cohort not treated with lumasiran”
Treatment with lumasiran resulted in substantial reductions in plasma oxalate in PH1 patients with chronic kidney disease stages 3b-5, with or without dialysis, with the drug demonstrating an acceptable safety profile through Month 6. Mild injection site reactions were the most common drug-related adverse event.
Results from a separate modeling analysis evaluating long-term kidney failure risk among PH1 patients treated with lumasiran were also presented.